The use of an angiotensin II antagonist (saralasin) as an adjunct during renal vein catheterization.
Renal vein catheterization was performed in fifteen hypertensive patients with unilateral renal disease. Samples for measurement of plasma renin concentration were obtained from each of the two renal veins and from the femoral artery (or the inferior caval vein)-before and during saralasin infusion. Saralasin infusion induced a significant decrease in blood pressure. In ten patients with lateralization of renin secretion before infusion, saralasin induced a 2-fold increase of the renin gradient across the diseased kidney, whereas there was no significant renin gradient across the contralateral kidney neither before nor after saralasin infusion. Thus, the renal venous renin ratio (diseased/contralateral) increased from a mean value of 2.10 to 4.13. In five patients without lateralization of renin secretion prior to infusion, saralasin induced a significant increase of renin gradient across both kidneys. In consequence, evidence for lateralization did not emerge and the renal vein renin ratio remained unchanged at 1.10. In cases with lateralization of renin secretion, the use of saralasin provides confirmatory evidence for strictly unilateral renin secretion with suppression of renin output from the contralateral kidney. In patients without obvious lateralization of renin secretion before saralasin, the administration of this angiotensin II inhibitor can serve to demonstrate a potential renin for renin secretion, shared by both kidneys.
D000804:Angiotensin II / Q000031:analogs & derivatives*; D001794:Blood Pressure / Q000187:drug effects*; D002404:Catheterization; D006801:Humans; D006977:Hypertension, Renal / Q000175:diagnosis* / Q000378:metabolism; D012082:Renal Veins; D012083:Renin / Q000378:metabolism; D012504:Saralasin / Q000494:pharmacology*
D000804:Angiotensin II; D012083:Renin; D012504:Saralasin